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Abstract
AIM
To verify the utility of treatment with fecal microbiota 
transplantation (FMT) in patients with irritable bowel 
syndrome (IBS).
METHODS
We searched EMBASE, Cochrane Library and PubMed 
in March, 2017. The reviewed literature was based 
on two systematic searches in each of the databases. 
The MeSH terms used were IBS and fecal microbiota 
transplantation and the abbreviations IBS and FMT. 
Reference lists from the articles were reviewed to 
identify additional pertinent articles. 
RESULTS
A total of six conference abstracts, one case report, 
one letter to the editor, and one clinical review were 
included. In the final analysis, treatment of 48 patients 
was evaluated. Treatment revealed an improvement 
in 58% of cases. The varying structure of the nine 
included studies must be taken into consideration.
CONCLUSION
Data on FMT and IBS are too limited to draw sufficient 
SYSTEMATIC REVIEWS
Submit a Manuscript: http://www.f6publishing.com
DOI: 10.3748/wjg.v23.i22.4112
4112 June 14, 2017|Volume 23|Issue 22|WJG|www.wjgnet.com
World J Gastroenterol  2017 June 14; 23(22): 4112-4120
 ISSN 1007-9327 (print)  ISSN 2219-2840 (online)
conclusions. Standardized double blinded randomized 
clinical trials need to be carried out to evaluate the 
effect of FMT on IBS.
Key words: Fecal microbiota transplantation; Microbiota; 
Irritable bowel syndrome
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: In humans, the gastrointestinal tract 
represents a large microbial ecosystem, housing 
several tr i l l ion microbial cel ls named the gut 
microbiota. Recent advances in sequencing methods 
have increased our understanding of the role of the 
gut microbiota in health and disease. Worldwide, 
interest is growing rapidly for fecal microbiota 
transplantation (FMT) as an “ecological” therapy for 
several diseases. Evidence suggests that a disturbance 
in the gut microbiota may be responsible for the 
initiation and persistence of symptoms in patients with 
irritable bowel syndrome. FMT could, therefore, be an 
ideal treatment option.
Halkjær SI, Boolsen AW, Günther S, Christensen AH, Petersen 
AM. Can fecal microbiota transplantation cure irritable bowel 
syndrome? World J Gastroenterol 2017; 23(22): 4112-4120 
Available from: URL: http://www.wjgnet.com/1007-9327/full/
v23/i22/4112.htm  DOI: http://dx.doi.org/10.3748/wjg.v23.
i22.4112
INTRODUCTION
There is a growing interest in fecal microbiota 
transplantation (FMT) therapy for several gas­
trointestinal (GI) disorders. Treating GI disorders with 
FMT has been attempted as early as the 4th century, 
where a Chinese physician named Ge Hong advised 
patients suffering from severe diarrhea to consume 
fresh stool from a healthy neighbor as a form of 
treatment[1]. It is thought that the microbiome in 
our GI system plays an important role in health and 
disease. Literature in this area has increased markedly 
over recent years. More than 90% of the nearly 4000 
articles indexed by PubMed on the subject have been 
published in the past five years (data from 2014)[2], 
indicating the rapidly growing interest within this field. 
Our knowledge of the microbiome is expanding due to, 
amongst other things, the development of new genetic 
technologies that allow us to identify and quantify 
the organisms of the microbiome at a faster rate[2]. 
Treatment with FMT has been a huge success when 
treating Clostridium difficile infection (CDI), with 33 
case studies and a single randomized clinical trial (RCT) 
showing efficacy rates ranging from 81%­94%[1]. 
An increasing number of studies demonstrate an 
aberrant gut microbiota composition in irritable bowel 
syndrome (IBS)[3­6] and raise the question of whether 
FMT has a place in the treatment of this condition. 
The microbial pathophysiology of IBS is, however, 
not clearly understood, as microbiota alterations in 
IBS might either be a cause of IBS or a consequence 
of intestinal secretion and motility altered by IBS. 
FMT may play a significant role in future treatment of 
several other diseases which are thought to be linked 
to an abnormal gut microbiota, such as metabolic 
syndrome[1], inflammatory bowel disease (IBD)[1], 
obesity, type 2 diabetes mellitus, colonization of the 
gastrointestinal tract by pathogenic and multi­resistant 
microorganisms[7], depression, autism spectrum 
disorders[8], and chronic stress[9]. 
IBS is the most prevalent functional GI disorder in 
developed countries. It is estimated that IBS affects 
10%­15% of the adult population[10] and strongly 
impairs quality of life, work productivity, and social 
function as well as inflicting substantial costs to health 
care systems[11,12]. 
The pathogenesis of IBS is complex and not yet 
fully understood. Accumulating evidence indicates 
that the gut microbiota plays a significant role[13], and 
alterations in gut microbiota among IBS patients have 
been described frequently[14]. It is also postulated that 
gut motility, enhanced visceral hypersensitivity, post 
infectious states[15], food sensitivity[2], genetics[16,17], 
and psychosocial disturbances[14] play a role in the 
pathophysiology of IBS. 
IBS symptoms are characterized by chronic 
abdominal pain and altered bowel habits, including 
diarrhea and/or constipation, in the absence of organic 
or structural causes[2]. To receive the diagnosis IBS, 
symptoms must concur with the Rome Ⅲ criteria[18]. 
Furthermore, IBS can be subcategorized into diarrhea 
predominant (IBS­D), constipation predominant 
(IBS­C), and alternating (IBS­A) or mixed (IBS­M), 
where the last two are sometimes considered 
synonymous[19]. In most patients, IBS is a chronic 
relapsing disease in which symptoms and IBS subtype 
may vary over time. IBS affects women more often 
than men[10].
The treatment of IBS remains challenging due to 
the heterogeneity of the disorder, a lack of reliable 
outcome measures, and high placebo response rates. 
At present, there is no cure for IBS and, while there 
are a number of pharmacological therapies available 
to treat IBS symptoms, they are not effective in many 
patients[20].
An improved understanding of microbiota in IBS 
is important not only with regard to its pathogenesis 
but also in enabling therapeutic modulation of the 
microbiota. Many medical and alternative therapies 
have been tested without convincing effects.
Some studies indicate that moderate effects can 
be achieved by probiotics and prebiotics[21,22]. These 
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products must, however, be taken continuously to 
obtain a lasting effect[23]. Also, treatment with tricyclic 
antidepressants, antibiotics, anti­cholinergic drugs, 
motility regulatory drugs, selective serotonin reuptake 
inhibitors, melatonin, non­steroid anti­inflammatory 
drugs, opioids, and even Chinese herbs are suggested 
in severe IBS cases and underlines the fact that we do 
not yet know the etiology of the disease.
Many patients report that their symptoms are 
related to various food items and two­thirds of IBS 
patients report dietary restrictions on this basis[24]. 
Many different dietary approaches for the management 
of IBS symptoms have been tested over the years. 
Although dietary interventions for IBS are frequently 
recommended, there is, however, a lack of data to 
support their use[25]. This impact highlights the need 
for more effective IBS treatments as current therapies 
are not successful in many patients. This review aims 
to investigate current evidence about FMT and its use 
in IBS.
MATERIALS AND METHODS
Literature search
The reviewed literature was based on two systematic 
searches performed on March 13th, 2017 in the 
databases PubMed, Cochrane Library and EMBASE. 
The MeSH terms used were irritable bowel syndrome 
and fecal microbiota transplantation and the ab­
breviations IBS and FMT. 
One hundred and fifty­eight papers were dis­
covered in the 6 searches and 9 additional records 
were found by going through reference lists and 
other sources. Seventy­two papers were assessed; 
where one unobtainable and 63 others were excluded 
since they were reviews and referred to the same 3 
original studies. Of these 3 studies, 2 were recovered 
but the 3rd could not be found[26]. The authors of this 
3rd study have made a clinical review, in which they 
mention their study. This review has been included 
instead[27]. A total of 9 papers were found from 
scrutinizing references, 3 articles were retrieved from 
the 6 searches made, and 3 were found from other 
sources. Nine papers were, therefore, included in 
the final review. Of the 9 articles, 6 are conference 
abstracts[28­33], 1 is a case report[34], 1 is a letter to the 
editor[35], and 1 is a review[27]. A PRISMA (http://www.
prisma­statement.org/statement.htm) flow diagram 
illustrates the outcome of the search (Figure 1). 
All studies evaluating the effects of FMT in IBS 
patients are included in this paper. To estimate the 
overall effect of FMT in IBS patients, we decided to 
include studies with a follow­up longer or equal to 3 
mo. Due to the restricted number of FMT studies in IBS 
patients, we have also decided to include conference 
abstracts.
RESULTS
A limited number of studies (summarized in Table 1) 
have examined the therapeutic role of FMT in IBS. 
The 9 publications reviewed in this paper consisted 
of 6 conference abstracts, 1 case report, 1 letter to 
the editor, and 1 clinical review. The studies are all 
case reports or case series and include a total of 127 
patients. Borody et al[35] describe the treatment of 
55 patients with FMT. The administration route of the 
FMT is not specified. What is stated is that the original 
bowel flora was removed by gastrointestinal lavage 
and replaced with bowel bacteria from a healthy donor. 
The 55 patients were suffering from constipation, 
diarrhoea, abdominal pain, ulcerative colitis, or 
Crohn’s disease. Patients were included if other 
forms of therapy had failed to ease their symptoms. 
Unfortunately, a distinction between patient groups 
was not made. Of the 55 patients, 20 (36.4%) were 
described as “cured”, 9 (16.4%) experienced a 
decrease of symptoms, and 26 (47.3%) experienced 
no improvement in symptoms. 
Andrews et al[34] published a case report of a 
patient with chronic constipation who they, in a 
separate publication, diagnosed with constipation­
predominant IBS[36]. The patient presented with a 
history of constipation spanning 3 years after an 
uncomplicated hysterectomy. Defaecation was once 
per week and required the use of laxatives. Associated 
symptoms included abdominal bloating, daily nausea, 
mild oesophageal reflux symptoms, and frequent 
headaches. The patient was given a treatment of 
vancomycin 250 mg thrice daily for 4 wk. Her con­
stipation and associated symptoms disappeared 
promptly, but returned within 3 d of seponating 
treatment. Andrews et al[34] then decided to continue 
treatment with FMT. A fresh suspension of faeces 
was collected from her spouse and infused by enema 
for 2 d. Within 3 d of treatment, her stool frequency 
had shifted to 1­2 times per day without the use of 
laxatives. The headaches, abdominal bloating, and 
reflux symptoms had also disappeared. Symptom 
improvement was sustained at 18 mo follow­up. 
The work of Borody et al[26] has not been acquired, 
despite extensive searching. Instead, the clinical 
review by Borody et al[27] is included as a substitute 
and describes the same case series from 2001. In 
2001, Borody et al[27] published a case series study 
of ulcerative colitis and chronic constipation with 3 
patients in each series. Chronic constipation was 
described as constipation­predominant IBS. Patients 
received single daily retention enemas for 5 d with 
donor stool suspended in 200 mL water with NaCl and 
a tablespoon of Psyllium. The patients with chronic 
constipation experienced a restoration of normal bowel 
function with a frequency of defaecation of 1­2 times 
per day. The follow­up period ranged from 8 to 28 mo 
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symptoms in 70% of the included patients. Factors 
which improved or resolved included abdominal pain 
(72%), changes in bowel habit (69%), dyspepsia 
(67%), bloating (50%), flatus (42%), and improved 
quality of life (42%). Transient increase in flatus was 
the only adverse effect reported[28,37]. 
Holvoet et al[29] carried out a prospective pilot 
study where 12 patients with refractory IBS symptoms 
underwent FMT. Patients with symptoms of severe 
bloating were included in the study. Fresh stool, 
under 6 hours after donation, were administered 
to the right colon via colonoscopy. The treatment 
was considered effective if the patient experienced 
an adequate relief of symptoms at week 12 post­
transplantation. As secondary end points, the authors 
monitored IBS symptom scores and quality of life via 
questionnaires. At week 4 and week 12, 67% and 
75% of patients reported an adequate relief of general 
IBS symptoms and, in particular, improvements 
in both case series. 
In 2013, Pinn et al[28] carried out a follow­up study 
of IBS treatment with FMT. Diagnosis of participants 
was based on the Rome Ⅲ criteria and patients, who 
were otherwise unresponsive to traditional treatment, 
were included in the study. Traditional treatment 
included probiotics, antibiotics, dietary changes, and 
other therapeutic modalities[28,37]. Thirteen of 15 eligible 
patients completed the study and were grouped 
in diarrhoea or constipation predominant IBS or 
mixed IBS. A questionnaire with 41 items addressing 
demographic data, pre­ and post­FMT data, severity of 
abdominal pain, bloating, flatus, dyspepsia, diarrhoea, 
constipation, and overall well­being were filled out 
by the participants. Nine patients had IBS­D, 3 had 
IBS­C and 1 had IBS­M. The abstract does not include 
a description of how the FMT was administered[28]. 
Average time from FMT to data collection was 11 
mo (range: 6­18 mo). FMT resolved or improved 
PRISMA 2009 Flow Diagram
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Figure 1  Results from the literature search for studies describing fecal microbiota transplantation in irritable bowel disease patients.
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in bloating, respectively. Furthermore, 16s rRNA 
amplicon sequencing was carried out on stool samples 
taken at different time points before and following 
transplantation. No 16s RNA results were presented 
in this paper[29]. In a subsequent journal letter written 
by Holvoet et al[38] further results were, however, 
presented. They found that the positive effects on 
IBS­related symptoms were linked to changes in the 
microbiota as a result of FMT treatment. Their stool 
sample analysis showed no microbiota community 
differences between patients and donors. Furthermore, 
no difference in microbial dissimilarity between patient­
donor responders and non­responder pairs at baseline 
was found. A trend of higher Streptococcus counts was 
seen in donors compared to patients, and successful 
donors tended to have higher counts of Streptococcus 
compared with donors without success. In responders, 
a trend of higher enrichment potential compared with 
non­responders was also observed. Furthermore, 
the median number of successfully transferred phy­
lotypes was higher in responders in relation to non­
responders. The responders to FMT were assessed at 
a 1 year follow­up, where 7/9 (78%) still reported a 
significant relief of symptoms. The use of the Rome Ⅲ 
criteria was utilized in this work[38].
In 2015, Cruz Aguilar et al[30] published an abstract 
in which they summarise the treatment and results of 
9 patients suffering from IBS. Five patients had IBS­D 
and 4 had IBS­C. Patients received a pre­treatment of 
rifaximin and, 3 wk later, a single FMT was performed 
during a colonoscopy. Evaluation of the treatment 
was performed 3 mo after FMT using a standardized 
questionnaire [Rome Ⅲ, Patient Health Questionnaires, 
Short Form Health Survey (36 items)] and clinical 
evaluation. Furthermore, deep sequencing analysis was 
performed on the microbiome before and 12 wk after 
FMT. The IBS­D patients immediately experienced a 
reduction of 2.5 points in the Bristol Stool Scale (BSS) 
score. No change in BSS score was reported in the 
IBS­C patients. A 50% reduction of abdominal pain 
was reported by 66% of the patients. A 50% reduction 
in bloating was reported by 16% of the participants. 
Reduction of symptoms lasted only 8 wk after FMT 
before a gradual reinstatement of symptoms occurred. 
Changes of the microbiome were seen in both IBS­D 
and IBS­C patients. In The IBS­D patients, a more 
diverse flora were discovered after treatment[30]. 
In 2016, Hong et al[31] published an abstract on 
FMT treatment in 10 patients with moderate IBS that 
did not respond to traditional treatment. Diagnosis 
was based on the Rome Ⅲ criteria and healthy donors 
were selected from family members and screened for 
infectious diseases before donation. It is not specified 
through which route the FMT was administrated or how 
the FMT was performed. Patients answered the IBS 
severity score before as well as 1 and 3 mo after FMT. 
Study outcomes included the length of symptom­free 
intervals, bloating, flatus, abdominal pain, frequency 
of bowel movements, dyspepsia, and overall well­
being before and after FMT. Eighty percent of the study 
participants experienced resolution or improvement of 
symptoms after FMT. According to their IBS severity 
score (231 ± 110), patients’ symptoms did, however, 
tend to return to their pre­treatment state within 3 
mo after FMT. Clinically significant improvements in 
IBS severity score were observed at only 1 mo follow­
up after FMT (132 ± 100) compared to baseline (252 
± 122) (P = 0.027). No long­term side­effects was 
reported by patients[31].
 Mazzawi et al[33] conducted a study with FMT 
in IBS­D patients in order to investigate the effect 
of FMT on symptoms and the density of duodenal 
enteroendocrine cells. Nine patients were included 
according to the Rome Ⅲ criteria. The FMT consisted of 
freshly donated stool from relatives. Details concerning 
how the FMT was administrated and performed were 
not included. Apart from the IBS severity score, the 
IBS symptom questionnaire and Bristol stool form 
scale were completed before and 3 wk after FMT. IBS 
symptom scores were significantly reduced 3 wk after 
FMT treatment; abdominal pain (P = 0.005), diarrhea 
(P = 0.0002), constipation (P = 0.02), nausea (P = 
Table 1  List of articles included in the review examining the treatment of irritable bowel syndrome with fecal microbiota 
transplantation
Ref. Year Type n N in regard to 
IBS
Subcategory
IBS-D IBS-C IBS-M
Borody et al[35] 1989 Letter to the editor 55 Not specified - - -
Andrews et al[34] 1992 Case report   1   1 - 1 -
Borody et al[27] 2004 Review   6   3 - 3 -
Pinn et al[28] 2013 Conference abstract 13 13 9 3 1
Holvoet et al[29] 2015 Conference abstract 12 12 - - -
Cruz Aguilar et al[30] 2015 Conference abstract   9   9 5 4 0
Hong et al[31] 2016 Conference abstract 10 10 - - -
Syzenko et al[32] 2016 Conference abstract 12 12 6 5 1
Mazzawi et al[33] 2016 Conference abstract   9   9 - - -
IBS: Irritable bowel syndrome.
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0.004), and anorexia (P = 0.096). Furthermore, total 
IBS severity scores and Bristol stool scale scores were 
significantly reduced 3 wk after FMT (P = 0.0002 and 
P = 0.02)[33].
Syzenko et al[32] published an abstract in 2016 on 
a study evaluating the effect of FMT in “treatment 
resistant” IBS patients. Twelve patients were enrolled 
according to the Rome Ⅲ criteria, including 6 with 
IBS­D, 5 with IBS­C, and 1 with IBS­M. Treatment 
resistance was defined as continuous GI symptoms 
after adequate lifestyle modification, as well as 
antibiotic, pre­ and probiotic, and antipsychotic 
treatment. FMT was accomplished via colonoscopy 
with or without consecutive enemas. To quantify 
the severity of GI symptoms, all patients registered 
eventual abdominal pain, bloating, and flatus according 
to the VAS scale. Bowel habits were evaluated 
using the Bristol stool scale and through frequency 
assessment. The results showed an abdominal pain 
resolution or significant improvement in 9 (75%) 
patients (P ≤ 0.01). Only 1 patient reported no 
change in pain level. Normalization of stool frequency 
and consistency was reported in all IBS­M and IBS­D 
patients. In IBS-C patients, a significant reduction in 
frequency of laxative using was reported (P ≤ 0.01). 
They also observed a significant improvement or 
complete resolution of symptoms in 7 (58.3%) and 
4 (33.3%) patients, respectively. No date for time of 
assessment of the study’s data has been provided[32].
In total, this review includes 9 published abstracts 
that describe 118 patients treated with FMT. Since the 
criteria for the diagnosis of the 55 included patients 
were not specified in the study by Borody et al[35], the 
results have been excluded from this paper. The results 
from Syzenko et al[32] and Mazzawi et al[33] have also 
been excluded. Syzenko et al[32] did not describe when 
the outcome data was measured. Mazzawi et al[33] had 
their follow­up after 3 wk ­ a period rated too short 
according to our criteria for evaluation of treatment 
effect. Therefore, the total number of treated patients 
with IBS included in this review is 48. Andrews et 
al[34], Borody et al[27], Pinn et al[28], and Holvoet et 
al[29] reported improvements in symptoms in 1, 3, 9, 
and 9 patients, respectively. Hong et al[31] reported 
no effect in 10 patients. Because of the manner in 
which Cruz Aguilar et al[30] present their results, it 
is difficult to give an exact number of patients who 
experienced symptom improvement. Since 6 (66%) 
patients experienced a 50% reduction in abdominal 
pain, abdominal pain has been chosen as the most 
significant parameter in evaluating FMT effect. A 
total of 28 of 48 patients (58%) experienced an 
improvement of symptoms upon review of the existing 
literature. No serious adverse effects were reported in 
any of the 9 included studies. 
DISCUSSION
Current evidence suggests that the microbiota of 
the GI tract is a significant factor in the aetiology of 
IBS. Several aspects support this: the onset of IBS 
after infectious gastroenteritis[15], transient relief of 
symptoms after antibiotic treatment[15], previous 
reports of the successful treatment of Clostridium 
difficile infection with FMT[1], improvements of 
symptoms in combination with probiotic treatment[22], 
and findings of an altered gut microbiome combined 
with improvement in IBS­D patients after FMT[30]. 
Holvoet et al[38] ascribed the positive effects of FMT on 
IBS­related symptoms to changes in the microbiota. 
Furthermore, orally administered antibiotic drugs that 
are poorly absorbed through the GI tract result in a 
temporarily reduction of symptoms[39]. The aetiology 
of IBS is complex and, though it is not certain that it is 
of bacterial origin, the treatment with FMT appears to 
be beneficial with an improvement in 58% of patients 
treated. Several factors make a comparison of existing 
studies difficult, however. Holvoet et al[29] included 
patients with refractory IBS symptoms and severe 
bloating, Hong et al[31] included IBS patients who 
were moderately or fully unresponsive to traditional 
treatment, Cruz Aguilar et al[30] and Mazzawi et al[33] 
included patients with diarrhoea predominant IBS, 
Pinn et al[28] and Syzenko et al[32] divided their patients 
into 3 groups of IBS­D, IBS­C and IBS­M, and Borody 
et al[27] included 3 patients with chronic constipation. 
None of the included studies specify how patient 
subgroups were categorised or diagnosed. Additionally, 
the method used to evaluate symptom relief, if 
specified at all, varied. Borody et al[27] failed to clarify 
how improvement was assessed. In the abstract from 
1989[35], the group describe their patients as “cured” 
but the definition of cure was not specified. In the 
study by Pinn et al[28], a 41­point­questionnaire was 
used with an average time from FMT to data collection 
of 11 mo, while Cruz Aguilar et al[30] used clinical 
evaluation and a standardized questionnaire with data 
collection 3 mo after FMT. Holvoet et al[29] also used 
questionnaires for quality of life but did not specify 
how patients reported relief of IBS symptoms 12 wk 
post FMT[29]. Cruz Aguilar et al[30], Pinn et al[37], Holvoet 
et al[29,38] Hong et al[31], Syzenko et al[32], and Mazzawi 
el al[33] used the ROME Ⅲ criteria. These criteria are, 
however, not mentioned in Andrews et al[34] or the 
articles by Borody[27] and his group. 
Differences between the 9 studies make it difficult 
to verify findings and reproduce results. The absence 
of the Rome Ⅲ criteria from some of the included 
studies[27,34,35] could be explained by the fact that the 
Rome Ⅲ criteria were only first published in 2006[19]. 
The included studies in our review do, however, lay 
the ground work for larger scale clinical trials by 
attempting FMT in several subgroups of IBS.
Consensus over the use of internationally accepted 
guidelines is needed to ensure that patients are sorted 
into predefined groups according to symptoms and 
diagnosis in order to accurately elucidate subgroup 
differences and FMT effect. Additional research should 
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also include the microbiome of donors so that donors 
with advantageous microbiomes can be matched with 
a specific subtype of IBS or any other FMT­treatable 
GI disorder. The RCTs of the future should implement 
standard criteria, such as the ROME Ⅲ criteria, when 
diagnosing patients. Six out of the 8 RCTs currently 
listed on clinicaltrials.gov (15/3­2017) use or refer to 
the Rome Ⅲ criteria. 
Holvoet et al[29] and Cruz Aguilar et al[30] made 
efforts to map the GI­microbiome associated with 
IBS before, during, and after their trials. This has 
not been accomplished earlier most likely because of 
lack of or access to necessary technology. Access to 
such technology is now becoming more widespread 
and rapid identification and quantification of the 
highly diverse organisms that comprise the human 
microbiome is becoming a reality[2]. In the case of 
Cruz Aguilar et al[30], their 5 IBS­D patients displayed 
a higher degree of microbiome diversity after FMT, but 
it is not specified what kind of bacteria this diversity 
included. The IBS­C patients also showed a change 
in gut microbiota, but this change was not further 
elaborated on[30]. Holvoet et al[29] failed to mention 
any results regarding the sequencing of 16s rRNA in 
their trial. In a later letter, they did, however, link the 
positive effects on IBS­related symptoms to changes in 
the microbiota as a result of FMT treatment[38]. Further 
sequencing of the microbiome is needed from larger 
groups to ascertain a broader picture of what a healthy 
microbiome consists of. This could be done through 
screening of healthy stool donors. 
In only 1[38] of the 9 core studies, a placebo effect 
was mentioned. Placebo has a large effect in clinical 
trials concerning IBS and ranges from 16%­71%[40]. 
The currently ongoing clinical trials listed above are 
all placebo controlled and mainly include patients 
with diarrhoea predominant IBS. Furthermore, there 
is a risk of positive outcome bias when dealing with 
small trials and case reports in which researchers only 
publish cases where improvement was reported.
Several other factors could influence the effect 
of FMT, such as the route used for FMT, duration of 
treatment and quantity of fecal microbiota transplanted 
to the patient. There are many different ways in which 
FMT can be administered, including capsules, enemas, 
and colonoscopy. No clinical trials have compared FMT 
delivery routes in IBS and further trials are needed to 
determine the ideal route of FMT treatment in these 
patients[14]. Furthermore, it is unknown whether 1 
FMT treatment is enough or if FMT should be repeated 
for best effect. In the study by Hong et al[31], results 
suggest that FMT may only be beneficial for 1 mo. 
The positive effects seemed to decrease over time 
and symptoms tended to return to their pre­FMT state 
within 3 mo after FMT treatment.
A systematic review by Wang et al[41] found that 
FMT could result in serious adverse effects, even 
death. Looking into the actual cases, however, the 
adverse effects were mostly related to the mode of 
delivery rather than the actual FMT, e.g., one death 
was due to sedation issues before colonoscopy. Using 
an endoscope to administer the FMT is widely used 
and will always include the risk of perforation of the 
intestine. The use of encapsulated FMT as mode of 
delivery can circumvent this problem and is, therefore, 
an attractive alternative. There is a general opinion 
that thorough donor screening is necessary in order 
to avoid possible transfer of disease or pathogens[42]. 
No standardized donor screening protocol has yet 
emerged, however.
Currently, 8 FMT and IBS studies (15/3­2017) are 
registered on clinicaltrials.gov. These ongoing trials 
primarily focus on the beneficial effects of FMT on IBS. 
Secondary goals of these trials include research into 
the possible bacterial aetiology behind IBS. Several 
of these studies have included sequencing of bacteria 
before and after FMT which hopefully will reveal a 
pattern or give us clues as to where to look next. 
Few studies examining FMT in the treatment of 
IBS have been published. Despite the small number 
of patients reviewed in this paper and differences in 
study design between the included studies, it seems 
that there is an ­ at least temporary­ improvement 
in a large proportion of FMT treated patients. An 
improvement was seen in 58% of participating 
IBS patients. Randomized, double­blinded placebo 
controlled trials are, however, still lacking. Currently, 
8 studies (15/3-2017) fulfilling these aforementioned 
criteria (clinicaltrials.gov) are underway, and 
considerable leaps in knowledge on the effect of FMT 
in IBS is expected within the near future.
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